Help TB activist Phumeza Tisile #DefeatTheSilence and get her hearing back with implant surger.

Spending on TB research from private-sector companies dropped 11.8% from 2012 to 2013 to less than $100 million. The status quo of declining investment in developing new TB drugs must end.

Several organizations and individuals working on TB are concerned that some medical schemes may be refusing to cover the cost of linezolid for drug-resistant tuberculosis.

The Eastern Europe and Central Asia is home to the world’s only growing HIV/AIDS epidemic and is the single most-affected region by the spread of multidrug-resistant TB.

The symposium was held October 30 at the 2014 Union World Conference on Lung Health in Barcelona, Spain.

... in HIV, we have witnessed something unique—global social justice in response to one disease. We believe the lessons of HIV need to be expanded upon. A similar alliance of activism and scientific inquiry is needed for tuberculosis ...

Political will remains key barrier to deploying BRICS resources towards the development of a new generation of treatments for drug-resistant TB.

Andaleeb Rinquest remembers the moment she accepted, with certainty, the imminence of her own death.

Technical and operational ‘how-to’: practical considerations

We urge other academics, in South Africa and globally, to support the Treatment Action Campaign and its vital work with both your financial and intellectual assets. The TAC is the heart of the international AIDS movement – we cannot sit by and let that heartbeat still.